Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared with patients receiving placebo. Adjusted ...
Oct 11, 2023
0
20
The first-in-class novel human immunoglobulin G1 Fc fragment, efgartigimod, is efficacious and safe for patients with chronic or persistent primary immune thrombocytopenia, according to a study published online Sept. 28 in ...
Oct 6, 2023
0
4
For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is efficacious for achieving ...
Oct 5, 2023
0
1
A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ...
Sep 28, 2023
0
1
A team of medical researchers from Shanghai Jiaotong University School of Medicine, Central South University and the Second Affiliated Hospital of Anhui Medical University, all in China, has found evidence suggesting that ...
For outpatients with mild-to-moderate COVID-19, inhaled fluticasone furoate does not shorten time to symptom resolution, according to a study published in the Sept. 21 issue of the New England Journal of Medicine.
Sep 21, 2023
0
32
The psychedelic drug MDMA can reduce symptoms of post-traumatic stress disorder, researchers reported in a new study published Thursday.
Sep 17, 2023
0
14
A new drug to treat type 2 diabetes has been approved for use) in the UK. Tirzepatide (sold under the brand name Mounjaro) could be available for prescription by early 2024—subject to availability.
Sep 15, 2023
0
5
For adults with refractory or unexplained chronic cough, gefapixant leads to modest improvement in cough frequency, severity, and quality of life, according to a review published online Sept. 11 in the Journal of the American ...
Sep 11, 2023
0
1
The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage ...
Sep 11, 2023
0
1
